Bill Would End Double Inspections of California Plants

California’s 2,000 biomedical companies face an extra layer of regulation: The state requires drug and device manufacturers to undergo an inspection by the California Food and Drug Branch in addition to federally mandated FDA inspections. But a U.S. House bill introduced by Rep. Brian Bilbray (R-Calif.) would end the practice, barring states from requiring duplicative probes. The Science and Technology Regulatory Relief Act, H.R. 4056, would apply in all 50 states. However, California is the only state with a separate inspection program, Bilbray spokesman Fred Tayco said.
The GMP Letter